STEPHANE SIA: Open Payments
NPI 1376963975 · EASTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,976 in 77 payments from 11 companies in 2025. Trend: 2023 $596 · 2024 $269 · 2025 $1,976
Food & beverage: $1,976
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 15 | $524 |
| E.R. Squibb & Sons, L.L.C. | 13 | $266 |
| Vanda Pharmaceuticals Inc. | 12 | $222 |
| Teva Pharmaceuticals USA, Inc. | 10 | $218 |
| Neurocrine BioSciences, Inc. | 6 | $154 |
| Alkermes, Inc. | 6 | $143 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| ABBVIE INC. | 3 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $74 |
Products named: INVEGA SUSTENNA, COBENFY, AUSTEDO XR, INGREZZA, ARISTADA, Auvelity, HETLIOZ, FANAPT.
Industry payments across MD — which companies pay providers there.
